These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

521 related articles for article (PubMed ID: 19932412)

  • 1. Pharmacologic management of urinary incontinence, voiding dysfunction, and overactive bladder.
    Saks EK; Arya LA
    Obstet Gynecol Clin North Am; 2009 Sep; 36(3):493-507. PubMed ID: 19932412
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Overactive bladder: an update.
    Hashim H; Abrams P
    Curr Opin Urol; 2007 Jul; 17(4):231-6. PubMed ID: 17558264
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathophysiology of urinary incontinence, voiding dysfunction, and overactive bladder.
    Rahn DD; Roshanravan SM
    Obstet Gynecol Clin North Am; 2009 Sep; 36(3):463-74. PubMed ID: 19932410
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Zát'ura F; Vsetica J; Abadías M; Pavlík I; Schraml P; Brod'ák M; Villoria J; Sust M;
    Eur Urol; 2010 Jan; 57(1):145-52. PubMed ID: 19446951
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antimuscarinics for the treatment of overactive bladder: current options and emerging therapies.
    Hegde SS; Mammen M; Jasper JR
    Curr Opin Investig Drugs; 2004 Jan; 5(1):40-9. PubMed ID: 14983972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Serati M; Salvatore S; Uccella S; Cromi A; Khullar V; Cardozo L; Bolis P
    Eur Urol; 2008 Oct; 54(4):911-5. PubMed ID: 18036728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Editorial comment on: Cizolirtine citrate is safe and effective for treating urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Costantini E; Lazzeri M
    Eur Urol; 2010 Jan; 57(1):152-3. PubMed ID: 19446952
    [No Abstract]   [Full Text] [Related]  

  • 8. Editorial comment on: Cizolirtine citrate is safe and effective to treat urinary incontinence secondary to overactive bladder: a phase 2 proof-of-concept study.
    Soljanik I
    Eur Urol; 2010 Jan; 57(1):153. PubMed ID: 19446950
    [No Abstract]   [Full Text] [Related]  

  • 9. Overactive bladder pharmacotherapy: what does the future hold?
    Dmochowski RR
    BJU Int; 2007 Jun; 99 Suppl 3():13-6. PubMed ID: 17488368
    [No Abstract]   [Full Text] [Related]  

  • 10. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Kuo HC
    Eur Urol; 2008 Oct; 54(4):915-6. PubMed ID: 18036725
    [No Abstract]   [Full Text] [Related]  

  • 11. Editorial comment on: Urinary incontinence at orgasm: relation to detrusor overactivity and treatment efficacy.
    Roumeguère T
    Eur Urol; 2008 Oct; 54(4):916-7. PubMed ID: 18036722
    [No Abstract]   [Full Text] [Related]  

  • 12. Recent advances in the development of antimuscarinic agents for overactive bladder.
    Smith AL; Wein AJ
    Trends Pharmacol Sci; 2010 Oct; 31(10):470-5. PubMed ID: 20801529
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Behavioral treatment of urinary incontinence, voiding dysfunction, and overactive bladder.
    Burgio KL
    Obstet Gynecol Clin North Am; 2009 Sep; 36(3):475-91. PubMed ID: 19932411
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Solifenacin in the treatment of urgency and other symptoms of overactive bladder: results from a randomized, double-blind, placebo-controlled, rising-dose trial.
    Cardozo L; Hessdörfer E; Milani R; Arañó P; Dewilde L; Slack M; Drogendijk T; Wright M; Bolodeoku J;
    BJU Int; 2008 Nov; 102(9):1120-7. PubMed ID: 18990175
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New drug treatments for urinary incontinence.
    Robinson D; Cardozo L
    Maturitas; 2010 Apr; 65(4):340-7. PubMed ID: 20097022
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Diagnosis and management of dysfunctional voiding.
    Feldman AS; Bauer SB
    Curr Opin Pediatr; 2006 Apr; 18(2):139-47. PubMed ID: 16601493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacological treatment of overactive bladder: report from the International Consultation on Incontinence.
    Andersson KE; Chapple CR; Cardozo L; Cruz F; Hashim H; Michel MC; Tannenbaum C; Wein AJ
    Curr Opin Urol; 2009 Jul; 19(4):380-94. PubMed ID: 19448545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Achieving continence with antimuscarinic therapy for overactive bladder: effects of baseline incontinence severity and bladder diary duration.
    Wein AJ; Khullar V; Wang JT; Guan Z
    BJU Int; 2007 Feb; 99(2):360-3. PubMed ID: 17155987
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correlation between the Overactive Bladder questionnaire (OAB-q) and urodynamic data of Parkinson disease patients affected by neurogenic detrusor overactivity during antimuscarinic treatment.
    Palleschi G; Pastore AL; Stocchi F; Bova G; Inghilleri M; Sigala S; Carbone A
    Clin Neuropharmacol; 2006; 29(4):220-9. PubMed ID: 16855424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and video urodynamic characteristics of adult women with dysfunctional voiding.
    Chen YC; Kuo HC
    J Formos Med Assoc; 2014 Mar; 113(3):161-5. PubMed ID: 24630033
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.